Additional inherited mutations may also occur in other members of the BRCA1–BRCA2–HR pathway, such as partner and localizer of BRCA2 (PALB2) and BRCA1-interacting protein C-terminal helicase 1 ...

Because of the wide range of differences found between BRCA2- and BRCA1-associated breast tumours, factors other than HR deficiency alone must have important roles in the development of hereditary ...

New research suggests that BRCA1 and BRCA2 gene mutations lead to hereditary ovarian cancers through different pathways, but that these pathways may be similar to ones at work in sporadic ovarian ...

Inhibiting the action of a particular enzyme dramatically slows the growth of tumor cells tied to BRCA1 and BRCA2 genetic mutations ... via a disruptive DNA repair pathway termed alt-NHEJ ...

The BRCA1 and BRCA2 genes code for tumor suppressor proteins ... Studies have shown that BRCA1 plays important roles in several cellular pathways and loss of proper BRCA1 function can lead ...

The cancer-predisposition genes BRCA1 and BRCA2 belong to this pathway. When they are mutated, DNA damage accumulates and one's risk increases for developing several types of cancer, including ...

BSO not associated with increased risk for cardiovascular diseases, ischemic heart disease, or cerebrovascular disease.

SAN DIEGO, CA – June 3, 2014 – Pathway Genomics Corporation ... duplication analysis that can detect mutations in BRCA1 and BRCA2, the genes linked to breast, ovarian and other types of ...

Pharmacogenomics. 2012;13(13):1523-1535. 5-year survival for stage III and IV (%): carriers, 38.1; noncarriers, 24.5 Median survival: p = 0.002 5-year survival for stage III and IV: p < 0.001 [46 ...

The cancer-predisposition genes BRCA1 and BRCA2 belong to this pathway. When they are mutated, DNA damage accumulates and one’s risk increases for developing several types of cancer, including breast, ...

NEW YORK, Feb. 2, 2015 /PRNewswire-USNewswire/ -- Inhibiting the action of a particular enzyme dramatically slows the growth of tumor cells tied to BRCA1 and BRCA2 genetic mutations which ...

Pharmacogenomics. 2012;13(13):1523-1535. 5-year survival for stage III and IV (%): carriers, 38.1; noncarriers, 24.5 Median survival: p = 0.002 5-year survival for stage III and IV: p < 0.001 [46 ...